EANS-News: AGENNIX AG Appoints New Vice President of Clinical Development
Dr. Steven Simonson Hired to Lead Talactoferrin Sepsis Development Program
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. --------------------------------------------------------------------------------
Personnel
Subtitle: Dr. Steven Simonson Hired to Lead Talactoferrin Sepsis Development Program
Planegg/Munich (Germany), Princeton, NJ, USA and Houston, TX, USA (euro adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) today announced the appointment of Steven Simonson, M.D., M.H.S. as Vice President, Clinical Development, reporting to Dr. Rajesh Malik, the Company's Chief Medical Officer. In this newly-created position, Dr. Simonson will lead the Company's sepsis development program with oral talactoferrin.
Rajesh Malik, M.D., Chief Medical Officer, said, "I am delighted to have Dr. Simonson join the team at Agennix. He has extensive clinical, academic and industry experience, including running a sepsis clinical development program at a major international pharmaceutical company. He joins us at a critical time as we prepare to initiate our Phase II/III trial with talactoferrin in severe sepsis."
Dr. Simonson has fifteen years of pharmaceutical industry experience. Prior to joining Agennix, Dr. Simonson held several senior positions at AstraZeneca, most recently as Senior Director, Clinical Research, Infection Therapeutic Area. In this position, he served as the lead physician for a Phase II program in sepsis. Prior to his industry career, Dr. Simonson held several academic positions at Duke University Medical Center. He received his M.D. from Medical College of Wisconsin and a Masters degree in Health Sciences from Duke University School of Medicine. He is Board certified in Pulmonary, Critical Care and Internal Medicine.
About Agennix Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. There can be no guarantee that the Company will move talactoferrin forward in development for severe sepsis in a timely manner, if at all, or that talactoferrin will ultimately be approved for sale in any indication in any country. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Agennix(TM) is a trademark of the Agennix group.
end of announcement euro adhoc --------------------------------------------------------------------------------
Further inquiry note:
Agennix AG
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Tel.: +49 89 8565-2693
ir@agennix.com
In the USA: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Tel.: 609-524-5884
laurie.doyle@agennix.com
Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Tel.: +49 89 210 228 0
raimund.gabriel@mc-services.eu
Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Tel.: +44 207 936 9325
lwilliams@troutgroup.com
Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade
Original-Content von: AGENNIX AG i.L., übermittelt durch news aktuell